David Shaw’s Guardant Health GH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$188M Buy
1,255,658
+828,183
+194% +$90.1M 0.09% 235
2026
Q1
$39.5M Sell
427,475
-195,582
-31% -$19.6M 0.02% 764
2025
Q4
$63.6M Buy
623,057
+589,710
+1,768% +$52.8M 0.03% 594
2025
Q3
$2.08M Buy
+33,347
New +$1.81M ﹤0.01% 2951
2024
Q2
Sell
-109,943
Closed -$2.56M 4611
2024
Q1
$2.27M Sell
109,943
-26,086
-19% -$559K ﹤0.01% 2539
2023
Q4
$3.68M Sell
136,029
-90,063
-40% -$2.36M ﹤0.01% 2162
2023
Q3
$6.7M Buy
+226,092
New +$7.95M 0.01% 1572
2023
Q2
Sell
-490,671
Closed -$14.1M 4349
2023
Q1
$11.5M Buy
+490,671
New +$14M 0.01% 1254
2022
Q3
Sell
-9,400
Closed -$379K 5302
2022
Q2
$379K Buy
+9,400
New +$466K ﹤0.01% 4254
2021
Q4
Sell
-71,604
Closed -$8.95M 5510
2021
Q3
$8.95M Sell
71,604
-157,128
-69% -$18.7M 0.01% 1600
2021
Q2
$28.4M Sell
228,732
-39,970
-15% -$5.38M 0.02% 824
2021
Q1
$41M Buy
268,702
+224,549
+509% +$33.9M 0.04% 580
2020
Q4
$5.69M Buy
44,153
+33,248
+305% +$3.83M 0.01% 1773
2020
Q3
$1.22M Buy
+10,905
New +$998K ﹤0.01% 2732
2020
Q2
Sell
-10,587
Closed -$737K 4073
2020
Q1
$737K Buy
+10,587
New +$812K ﹤0.01% 2970

Other funds holding GH

David Shaw's GH Position: Q2 2026 in Review

David Shaw increased its Guardant Health (GH) stake by 194% in Q2 2026, buying an estimated $90.1M and bringing the position to 1,255,658 shares worth $188M. The position accounts for 0.09% of the portfolio, ranked #235.

David Shaw first reported a position in GH in Q1 2020 and has held it in 15 quarters since. 595 funds tracked by Wall St. Rank hold GH as of Q2 2026.

  • David Shaw held 1,255,658 shares of Guardant Health worth $188M as of Q2 2026.
  • David Shaw bought 828,183 Guardant Health shares in Q2 2026, an estimated $90.1M.
  • Guardant Health made up 0.09% of David Shaw's portfolio in Q2 2026, its #235 holding.
  • David Shaw first reported a position in Guardant Health in Q1 2020 and has held it in 15 quarters since.
  • 595 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.